Vasopressin as a possible contributor to hypertension

The role of vasopressin as a pressor agent to the hypertensive process was examined. Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Japanese circulation journal 1984-01, Vol.48 (2), p.188-195
Hauptverfasser: Yazaki, Y, Ohuchi, Y, Ashida, T, Tsai, R, Yoshizumi, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 195
container_issue 2
container_start_page 188
container_title Japanese circulation journal
container_volume 48
creator Yazaki, Y
Ohuchi, Y
Ashida, T
Tsai, R
Yoshizumi, M
description The role of vasopressin as a pressor agent to the hypertensive process was examined. Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment. Administration of DDAVP which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP. Furthermore, the pressor action of vasopressin appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension. Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension. An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of angiotensin II forming and receptor binding capacity for sodium balance in the brain. However, the role of vasopressin remains to be determined in human essential hypertension.
doi_str_mv 10.1253/jcj.48.188
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1253_jcj_48_188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>6321816</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-1ab8e3cbd6bace737df8ba23eca7ebb3ae4193bda2db56219c1c2afc8db328c23</originalsourceid><addsrcrecordid>eNo9j0tLw0AUhQdRaq1u3AuzFhLnziO5WUqxKhTcqNthXsGENgkz6aL_3pEWV-csPg7nI-QeWAlciafe9aXEEhAvyBKErAuJorkkS8ZyB-R4TW5S6hnjtVRqQRaV4IBQLYn6NmmcYkipG6hJ1NBpzN3uAnXjMMfOHuYx0nmkP8cpxDkMqRuHW3LVml0Kd-dcka_Ny-f6rdh-vL6vn7eFk6jmAozFIJz1lTUu1KL2LVrDRXCmDtYKEyQ0wnrDvVUVh8aB46Z16K3g6LhYkcfTrov5VQytnmK3N_Gogek_dZ3VtUSd1TP8cIKng90H_4-eXcUvaWZWgQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Vasopressin as a possible contributor to hypertension</title><source>MEDLINE</source><source>J-STAGE日本語サイト (Free Access)</source><creator>Yazaki, Y ; Ohuchi, Y ; Ashida, T ; Tsai, R ; Yoshizumi, M</creator><creatorcontrib>Yazaki, Y ; Ohuchi, Y ; Ashida, T ; Tsai, R ; Yoshizumi, M</creatorcontrib><description>The role of vasopressin as a pressor agent to the hypertensive process was examined. Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment. Administration of DDAVP which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP. Furthermore, the pressor action of vasopressin appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension. Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension. An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of angiotensin II forming and receptor binding capacity for sodium balance in the brain. However, the role of vasopressin remains to be determined in human essential hypertension.</description><identifier>ISSN: 0047-1828</identifier><identifier>EISSN: 1347-4839</identifier><identifier>DOI: 10.1253/jcj.48.188</identifier><identifier>PMID: 6321816</identifier><language>eng</language><publisher>Japan</publisher><subject>Animals ; Blood Pressure - drug effects ; Chlorides - pharmacology ; Deamino Arginine Vasopressin - pharmacology ; Desoxycorticosterone - pharmacology ; Hypertension - chemically induced ; Hypertension - etiology ; Hypertension - physiopathology ; Injections, Intravenous ; Lithium - pharmacology ; Lithium Chloride ; Male ; Rats ; Receptors, Angiotensin - physiology ; Salts ; Vasopressins - pharmacology ; Vasopressins - physiology</subject><ispartof>Japanese circulation journal, 1984-01, Vol.48 (2), p.188-195</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-1ab8e3cbd6bace737df8ba23eca7ebb3ae4193bda2db56219c1c2afc8db328c23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6321816$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yazaki, Y</creatorcontrib><creatorcontrib>Ohuchi, Y</creatorcontrib><creatorcontrib>Ashida, T</creatorcontrib><creatorcontrib>Tsai, R</creatorcontrib><creatorcontrib>Yoshizumi, M</creatorcontrib><title>Vasopressin as a possible contributor to hypertension</title><title>Japanese circulation journal</title><addtitle>Jpn Circ J</addtitle><description>The role of vasopressin as a pressor agent to the hypertensive process was examined. Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment. Administration of DDAVP which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP. Furthermore, the pressor action of vasopressin appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension. Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension. An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of angiotensin II forming and receptor binding capacity for sodium balance in the brain. However, the role of vasopressin remains to be determined in human essential hypertension.</description><subject>Animals</subject><subject>Blood Pressure - drug effects</subject><subject>Chlorides - pharmacology</subject><subject>Deamino Arginine Vasopressin - pharmacology</subject><subject>Desoxycorticosterone - pharmacology</subject><subject>Hypertension - chemically induced</subject><subject>Hypertension - etiology</subject><subject>Hypertension - physiopathology</subject><subject>Injections, Intravenous</subject><subject>Lithium - pharmacology</subject><subject>Lithium Chloride</subject><subject>Male</subject><subject>Rats</subject><subject>Receptors, Angiotensin - physiology</subject><subject>Salts</subject><subject>Vasopressins - pharmacology</subject><subject>Vasopressins - physiology</subject><issn>0047-1828</issn><issn>1347-4839</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9j0tLw0AUhQdRaq1u3AuzFhLnziO5WUqxKhTcqNthXsGENgkz6aL_3pEWV-csPg7nI-QeWAlciafe9aXEEhAvyBKErAuJorkkS8ZyB-R4TW5S6hnjtVRqQRaV4IBQLYn6NmmcYkipG6hJ1NBpzN3uAnXjMMfOHuYx0nmkP8cpxDkMqRuHW3LVml0Kd-dcka_Ny-f6rdh-vL6vn7eFk6jmAozFIJz1lTUu1KL2LVrDRXCmDtYKEyQ0wnrDvVUVh8aB46Z16K3g6LhYkcfTrov5VQytnmK3N_Gogek_dZ3VtUSd1TP8cIKng90H_4-eXcUvaWZWgQ</recordid><startdate>19840101</startdate><enddate>19840101</enddate><creator>Yazaki, Y</creator><creator>Ohuchi, Y</creator><creator>Ashida, T</creator><creator>Tsai, R</creator><creator>Yoshizumi, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19840101</creationdate><title>Vasopressin as a possible contributor to hypertension</title><author>Yazaki, Y ; Ohuchi, Y ; Ashida, T ; Tsai, R ; Yoshizumi, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-1ab8e3cbd6bace737df8ba23eca7ebb3ae4193bda2db56219c1c2afc8db328c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Animals</topic><topic>Blood Pressure - drug effects</topic><topic>Chlorides - pharmacology</topic><topic>Deamino Arginine Vasopressin - pharmacology</topic><topic>Desoxycorticosterone - pharmacology</topic><topic>Hypertension - chemically induced</topic><topic>Hypertension - etiology</topic><topic>Hypertension - physiopathology</topic><topic>Injections, Intravenous</topic><topic>Lithium - pharmacology</topic><topic>Lithium Chloride</topic><topic>Male</topic><topic>Rats</topic><topic>Receptors, Angiotensin - physiology</topic><topic>Salts</topic><topic>Vasopressins - pharmacology</topic><topic>Vasopressins - physiology</topic><toplevel>online_resources</toplevel><creatorcontrib>Yazaki, Y</creatorcontrib><creatorcontrib>Ohuchi, Y</creatorcontrib><creatorcontrib>Ashida, T</creatorcontrib><creatorcontrib>Tsai, R</creatorcontrib><creatorcontrib>Yoshizumi, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Japanese circulation journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yazaki, Y</au><au>Ohuchi, Y</au><au>Ashida, T</au><au>Tsai, R</au><au>Yoshizumi, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vasopressin as a possible contributor to hypertension</atitle><jtitle>Japanese circulation journal</jtitle><addtitle>Jpn Circ J</addtitle><date>1984-01-01</date><risdate>1984</risdate><volume>48</volume><issue>2</issue><spage>188</spage><epage>195</epage><pages>188-195</pages><issn>0047-1828</issn><eissn>1347-4839</eissn><abstract>The role of vasopressin as a pressor agent to the hypertensive process was examined. Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment. Administration of DDAVP which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP. Furthermore, the pressor action of vasopressin appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension. Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension. An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of angiotensin II forming and receptor binding capacity for sodium balance in the brain. However, the role of vasopressin remains to be determined in human essential hypertension.</abstract><cop>Japan</cop><pmid>6321816</pmid><doi>10.1253/jcj.48.188</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0047-1828
ispartof Japanese circulation journal, 1984-01, Vol.48 (2), p.188-195
issn 0047-1828
1347-4839
language eng
recordid cdi_crossref_primary_10_1253_jcj_48_188
source MEDLINE; J-STAGE日本語サイト (Free Access)
subjects Animals
Blood Pressure - drug effects
Chlorides - pharmacology
Deamino Arginine Vasopressin - pharmacology
Desoxycorticosterone - pharmacology
Hypertension - chemically induced
Hypertension - etiology
Hypertension - physiopathology
Injections, Intravenous
Lithium - pharmacology
Lithium Chloride
Male
Rats
Receptors, Angiotensin - physiology
Salts
Vasopressins - pharmacology
Vasopressins - physiology
title Vasopressin as a possible contributor to hypertension
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T02%3A11%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vasopressin%20as%20a%20possible%20contributor%20to%20hypertension&rft.jtitle=Japanese%20circulation%20journal&rft.au=Yazaki,%20Y&rft.date=1984-01-01&rft.volume=48&rft.issue=2&rft.spage=188&rft.epage=195&rft.pages=188-195&rft.issn=0047-1828&rft.eissn=1347-4839&rft_id=info:doi/10.1253/jcj.48.188&rft_dat=%3Cpubmed_cross%3E6321816%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6321816&rfr_iscdi=true